467 related articles for article (PubMed ID: 7865316)
1. Immunization with virion-derived glycoprotein 130 from HIV-2 or SIV protects macaques against challenge virus grown in human or simian cells or prepared ex vivo.
Stahl-Hennig C; Coulibaly C; Petry H; Voss G; Dittmer U; Bodemer W; Makoschey B; Jurkiewicz E; Lüke W; Hunsmann G
AIDS Res Hum Retroviruses; 1994; 10 Suppl 2():S27-32. PubMed ID: 7865316
[TBL] [Abstract][Full Text] [Related]
2. Simian immunodeficiency virus (SIV) gp130 oligomers protect rhesus macaques (Macaca mulatta) against the infection with SIVmac32H grown on T-cells or derived ex vivo.
Luke W; Coulibaly C; Dittmer U; Voss G; Oesterle R; Makoschey B; Sauermann U; Jurkiewicz E; Stahl-Henning C; Petry H; Hunsmann G
Virology; 1996 Feb; 216(2):444-50. PubMed ID: 8607276
[TBL] [Abstract][Full Text] [Related]
3. Protection against SIV infection in macaques by immunization with inactivated virus from the BK28 molecular clone, but not with BK28-derived recombinant env and gag proteins.
Mills KH; Page M; Chan WL; Kitchin P; Stott EJ; Taffs F; Jones W; Rose J; Ling C; Silvera P
J Med Primatol; 1992; 21(2-3):50-8. PubMed ID: 1433267
[TBL] [Abstract][Full Text] [Related]
4. Immunization with class I human histocompatibility leukocyte antigen can protect macaques against challenge infection with SIVmac-32H.
Chan WL; Rodgers A; Grief C; Almond N; Ellis S; Flanagan B; Silvera P; Bootman J; Stott J; Kent K
AIDS; 1995 Mar; 9(3):223-8. PubMed ID: 7755909
[TBL] [Abstract][Full Text] [Related]
5. Vectored Gag and Env but not Tat show efficacy against simian-human immunodeficiency virus 89.6P challenge in Mamu-A*01-negative rhesus monkeys.
Liang X; Casimiro DR; Schleif WA; Wang F; Davies ME; Zhang ZQ; Fu TM; Finnefrock AC; Handt L; Citron MP; Heidecker G; Tang A; Chen M; Wilson KA; Gabryelski L; McElhaugh M; Carella A; Moyer C; Huang L; Vitelli S; Patel D; Lin J; Emini EA; Shiver JW
J Virol; 2005 Oct; 79(19):12321-31. PubMed ID: 16160159
[TBL] [Abstract][Full Text] [Related]
6. Whole inactivated SIV vaccine grown on human cells fails to protect against homologous SIV grown on simian cells.
Putkonen P; Nilsson C; Hild K; Benthin R; Cranage M; Aubertin AM; Biberfeld G
J Med Primatol; 1993; 22(2-3):100-3. PubMed ID: 8411101
[TBL] [Abstract][Full Text] [Related]
7. Immunization of Macaca fascicularis with inactivated SIV preparations: challenge with human- or monkey-derived SIV and the effects of a longer immunization schedule.
Titti F; Koanga Mogtomo ML; Borsetti A; Geraci A; Sernicola L; Panzini G; Turillazzi GP; Baroncelli S; Giovannetti A; Zamarchi R
J Med Primatol; 1993; 22(2-3):110-8. PubMed ID: 8411103
[TBL] [Abstract][Full Text] [Related]
8. Protection of vaccinia-primed macaques against SIVmne infection by combination immunization with recombinant vaccinia virus and SIVmne gp160.
Hu SL; Stallard V; Abrams K; Barber GN; Kuller L; Langlois AJ; Morton WR; Benveniste RE
J Med Primatol; 1993; 22(2-3):92-9. PubMed ID: 8411113
[TBL] [Abstract][Full Text] [Related]
9. Immunization with HIV-1 SF162-derived Envelope gp140 proteins does not protect macaques from heterologous simian-human immunodeficiency virus SHIV89.6P infection.
Xu R; Srivastava IK; Kuller L; Zarkikh I; Kraft Z; Fagrouch Z; Letvin NL; Heeney JL; Barnett SW; Stamatatos L
Virology; 2006 Jun; 349(2):276-89. PubMed ID: 16527321
[TBL] [Abstract][Full Text] [Related]
10. Cell-mediated immune response of macaques immunized with low doses of simian immunodeficiency virus (SIV).
Dittmer U; Spring M; Petry H; Nisslein T; Rieckmann P; Lüke W; Stahl-Hennig C; Hunsmann G; Bodemer W
J Biotechnol; 1996 Jan; 44(1-3):105-10. PubMed ID: 8717393
[TBL] [Abstract][Full Text] [Related]
11. A combination HIV vaccine based on Tat and Env proteins was immunogenic and protected macaques from mucosal SHIV challenge in a pilot study.
Ferrantelli F; Maggiorella MT; Schiavoni I; Sernicola L; Olivieri E; Farcomeni S; Pavone-Cossut MR; Moretti S; Belli R; Collacchi B; Srivastava IK; Titti F; Cafaro A; Barnett SW; Ensoli B
Vaccine; 2011 Apr; 29(16):2918-32. PubMed ID: 21338681
[TBL] [Abstract][Full Text] [Related]
12. Sequential immunization of macaques with two differentially attenuated vaccines induced long-term virus-specific immune responses and conferred protection against AIDS caused by heterologous simian human immunodeficiency Virus (SHIV(89.6)P).
Kumar A; Lifson JD; Li Z; Jia F; Mukherjee S; Adany I; Liu Z; Piatak M; Sheffer D; McClure HM; Narayan O
Virology; 2001 Jan; 279(1):241-56. PubMed ID: 11145906
[TBL] [Abstract][Full Text] [Related]
13. Reduction of viral loads by multigenic DNA priming and adenovirus boosting in the SIVmac-macaque model.
Suh YS; Park KS; Sauermann U; Franz M; Norley S; Wilfingseder D; Stoiber H; Fagrouch Z; Heeney J; Hunsmann G; Stahl-Hennig C; Sung YC
Vaccine; 2006 Mar; 24(11):1811-20. PubMed ID: 16274888
[TBL] [Abstract][Full Text] [Related]
14. Durable protection of rhesus macaques immunized with a replicating adenovirus-SIV multigene prime/protein boost vaccine regimen against a second SIVmac251 rectal challenge: role of SIV-specific CD8+ T cell responses.
Malkevitch NV; Patterson LJ; Aldrich MK; Wu Y; Venzon D; Florese RH; Kalyanaraman VS; Pal R; Lee EM; Zhao J; Cristillo A; Robert-Guroff M
Virology; 2006 Sep; 353(1):83-98. PubMed ID: 16814356
[TBL] [Abstract][Full Text] [Related]
15. Induction of HIV-specific antibody response and protection against vaginal SHIV transmission by intranasal immunization with inactivated SHIV-capturing nanospheres in macaques.
Miyake A; Akagi T; Enose Y; Ueno M; Kawamura M; Horiuchi R; Hiraishi K; Adachi M; Serizawa T; Narayan O; Akashi M; Baba M; Hayami M
J Med Virol; 2004 Jul; 73(3):368-77. PubMed ID: 15170630
[TBL] [Abstract][Full Text] [Related]
16. Protection of macaques against vaginal SHIV challenge by systemic or mucosal and systemic vaccinations with HIV-envelope.
Barnett SW; Srivastava IK; Kan E; Zhou F; Goodsell A; Cristillo AD; Ferrai MG; Weiss DE; Letvin NL; Montefiori D; Pal R; Vajdy M
AIDS; 2008 Jan; 22(3):339-48. PubMed ID: 18195560
[TBL] [Abstract][Full Text] [Related]
17. Heterologous envelope immunogens contribute to AIDS vaccine protection in rhesus monkeys.
Letvin NL; Huang Y; Chakrabarti BK; Xu L; Seaman MS; Beaudry K; Korioth-Schmitz B; Yu F; Rohne D; Martin KL; Miura A; Kong WP; Yang ZY; Gelman RS; Golubeva OG; Montefiori DC; Mascola JR; Nabel GJ
J Virol; 2004 Jul; 78(14):7490-7. PubMed ID: 15220422
[TBL] [Abstract][Full Text] [Related]
18. Protection of cynomolgus macaques (Macaca fascicularis) against infection with the human immunodeficiency virus type 2 strain ben (HIV-2ben) by immunization with the virion-derived envelope glycoprotein gp130.
Lüke W; Voss G; Stahl-Hennig C; Coulibaly C; Putkonen P; Petry H; Hunsmann G
AIDS Res Hum Retroviruses; 1993 May; 9(5):387-94. PubMed ID: 8318267
[TBL] [Abstract][Full Text] [Related]
19. Anti-cellular antibodies in sera from vaccinated macaques can induce complement-mediated virolysis of human immunodeficiency virus and simian immunodeficiency virus.
Spear GT; Takefman DM; Sullivan BL; Landay AL; Jennings MB; Carlson JR
Virology; 1993 Aug; 195(2):475-80. PubMed ID: 8337824
[TBL] [Abstract][Full Text] [Related]
20. Comparison of vaccine strategies using recombinant env-gag-pol MVA with or without an oligomeric Env protein boost in the SHIV rhesus macaque model.
Earl PL; Wyatt LS; Montefiori DC; Bilska M; Woodward R; Markham PD; Malley JD; Vogel TU; Allen TM; Watkins DI; Miller N; Moss B
Virology; 2002 Mar; 294(2):270-81. PubMed ID: 12009868
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
